CBL — Control Bionics Income Statement
0.000.00%
- AU$11.67m
- AU$11.51m
- AU$7.04m
- 39
- 42
- 23
- 26
Annual income statement for Control Bionics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.09 | 4.72 | 5.91 | 6.03 | 7.04 |
Cost of Revenue | |||||
Gross Profit | 2.66 | 2.74 | 3.98 | 4.58 | 5.01 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.67 | 10.8 | 11.5 | 11.9 | 13 |
Operating Profit | -3.58 | -6.08 | -5.61 | -5.86 | -5.93 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -3.55 | -6.1 | -5.63 | -5.91 | -6.11 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.55 | -6.1 | -5.63 | -5.91 | -6.11 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.55 | -6.1 | -5.63 | -5.91 | -6.11 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.55 | -6.1 | -5.63 | -5.91 | -6.11 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.044 | -0.064 | -0.051 | -0.036 | -0.023 |
Dividends per Share |